<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522180</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 766720-CS5</org_study_id>
    <secondary_id>2020-000675-20</secondary_id>
    <nct_id>NCT04522180</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly</brief_title>
  <official_title>An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy in Patients With Acromegaly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and efficacy of&#xD;
      IONIS-GHR-LRx subcutaneous (SC) injection as monotherapy in patients with acromegaly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, randomized, Phase 2 study of IONIS-GHR-LRx in up to 40&#xD;
      participants with acromegaly. Participants will be randomized to 1 of 3 treatment groups to&#xD;
      receive a single dose of IONIS GHR-LRx monthly for 73 weeks. At the end of 73 weeks,&#xD;
      participants will enter a 14-week post-treatment (PT) evaluation period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Insulin-like Growth Factor I (IGF-1) to Week 27</measure>
    <time_frame>Up to Week 27</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Normalized IGF-1 Levels to Within 1.2 Times of Gender and Age Limits at Day 183 (Week 27)</measure>
    <time_frame>At Week 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Normalized IGF-1 Levels to Within 1.0 Times of Gender and Age Limits at Day 183 (Week 27)</measure>
    <time_frame>At Week 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum IGF-1 Over Time</measure>
    <time_frame>Up to approximately 80 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum IGF-1 Over Time</measure>
    <time_frame>Up to approximately 80 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>IONIS-GHR-LRx Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of IONIS-GHR-LRx Dose 1 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IONIS-GHR-LRx Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of IONIS-GHR-LRx Dose 2 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IONIS-GHR-LRx Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of IONIS-GHR-LRx Dose 3 will be administered by SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-GHR-LRx</intervention_name>
    <description>IONIS-GHR-LRx will be administered by SC injection.</description>
    <arm_group_label>IONIS-GHR-LRx Dose 1</arm_group_label>
    <arm_group_label>IONIS-GHR-LRx Dose 2</arm_group_label>
    <arm_group_label>IONIS-GHR-LRx Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females with a documented diagnosis of Acromegaly* who are 18 to 75 years old&#xD;
             (inclusive) at the time of informed consent.&#xD;
&#xD;
          2. Have had pituitary surgery (e.g. transsphenoidal) unless there was a contraindication&#xD;
             to surgery and are either acromegaly medical treatment naïve, or who had not taken any&#xD;
             other acromegaly medications prior to the screening visit as outlined below&#xD;
&#xD;
               -  bromocriptine: 2 weeks&#xD;
&#xD;
               -  cabergoline: 4 weeks&#xD;
&#xD;
               -  quinagolide: 4 weeks&#xD;
&#xD;
               -  octreotide daily injection (SC) or oral formulation: 4 weeks&#xD;
&#xD;
               -  pegvisomant: 4 weeks&#xD;
&#xD;
               -  octreotide LAR: 3 months&#xD;
&#xD;
               -  pasireotide LAR: 4 months&#xD;
&#xD;
               -  lanreotide (all formulations): 3 months&#xD;
&#xD;
          3. At Screening, serum IGF-1 (performed at the central lab) between 1.3 to 5 × ULN,&#xD;
             inclusive, adjusted for age and sex.&#xD;
&#xD;
          4. Females must be non-pregnant and non-lactating, and either surgically sterile,&#xD;
             post-menopausal, abstinent, or using 1 highly effective method of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who received surgery for pituitary adenoma within the last 3 months&#xD;
             before the trial, and/or planning to receive surgery during the trial&#xD;
&#xD;
          2. Participants who received radiotherapy for pituitary adenoma within the last 2 years&#xD;
             before the trial, and/or planning to receive radiotherapy during the trial&#xD;
&#xD;
          3. Participants with a pituitary tumor that, per Investigator judgment, is worsening&#xD;
             (e.g., either growing or at risk of compressing or abutting the optic chiasm or other&#xD;
             vital structures) as assessed by pituitary/sellar MRI protocol at Screening or within&#xD;
             3 months of Screening. CT scan is allowed if MRI is contraindicated&#xD;
&#xD;
          4. Evidence of decompensated cardiac function per medical judgement and/or New York Heart&#xD;
             Association (NYHA) Class 3 or 4&#xD;
&#xD;
          5. Clinical evidence of symptomatic hyperprolactinemia that would necessitate treatment&#xD;
&#xD;
          6. Symptomatic cholelithiasis, and/or choledocholithiasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>(844) 415-1442</phone>
    <email>ionisNCT04522180study@clinicaltrialmedia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palm Research Center Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endocrinology Associates, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>East-Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Rīga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vaidoto Urbanaviciaus Individuali imone</name>
      <address>
        <city>Alytus</city>
        <zip>63246</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zespol Oddzialow Chorob Wewnetrznych, Endokrynologii i Diabetologii</name>
      <address>
        <city>Warszawa</city>
        <zip>03-242</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny, im. Jana Mikulicza-Radeckiego we Wroclawiu,</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych Piotr Napora Lekarze Sp. p.</name>
      <address>
        <city>Wrocław</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Unirea Bucuresti, Endocrinologie</name>
      <address>
        <city>Bucharest</city>
        <zip>060044</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>I.M. Sechenov Moscow First State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119146</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acromegaly</keyword>
  <keyword>IONIS-GHR-LRx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

